| 30.97 Data as of May 22 |  -0.55 / -1.74%Today’s Change | 29.39 Today|||52-Week Range 39.86 | -17.46% Year-to-Date |
| THOR Downgraded to Underperform - Analyst Blog May 21 / Zacks.com | Thoratec Is Now Oversold (THOR) May 20 / TheStreet.com |
| FDA Nod for Thoratec Controller - Analyst Blog May 20 / Zacks.com | 1 Reason Thoratec May Be Headed for a Slowdown May 13 / MotleyFool.com |
| Previous close | 31.52 |
| Today’s open | 31.58 |
| Day’s range | -- - -- |
| Volume | 821,682 |
| Average volume (3 months) | 657,213 |
| Market cap | $1.8B |
| Dividend yield | -- |
| Earnings growth (last year) | -21.01% |
| Earnings growth (this year) | -3.04% |
| Earnings growth (next 5 years) | +9.30% |
| Revenue growth (last year) | +16.31% |
| P/E ratio | 37.3 |
| Price/Sales | 4.42 |
| Price/Book | 3.04 |
| Today’s change | Today’s % change | |
|---|---|---|
| HTWRHeartWare Internatio... | -2.24 | -2.36% |
| CYBXCyberonics Inc | -1.39 | -2.81% |
| PCRXPacira Pharmaceutica... | +0.24 | +0.83% |
| CMNCantel Medical Corp | -0.73 | -2.11% |
| Next reporting date | July 30, 2013 |
| EPS forecast (this quarter) | $0.43 |
| Annual revenue (last year) | $491.7M |
| Annual profit (last year) | $56.2M |
| Net profit margin | 11.42% |
Sector Health Technology |
Industry Medical Specialties |
President, Chief Executive Officer & Director Gerhard F. Burbach, MBA |
CFO, VP & Senior Director-Investor Relations Taylor C. Harris |
Corporate headquarters Pleasanton, California |
.
